ANN ARBOR, Mich., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the closing of its previously announced underwritten public offering from which the Company received approximately $12.4 million in net proceeds from the sale of the units (including the partially exercised option of the over-allotment), after underwriting discounts and commissions and other offering expenses. The offering included the sale of 52,077,100 units in total (46,154,000 units from the public offering plus 5,923,100 units exercised-to-date from the over-allotment option) at a public offering price of $0.26 per unit. Oppenheimer & Co. Inc. acted as the sole underwriter for the offering.
